Drug intelligence / Profile preview

TRE-T20

Development stage: Preclinical
Lead developer: Cyclo Therapeutics
Modality: Small Molecules
Administration: Subcutaneous

Overview

TRE-T20 is a lead drug series developed by Cyclo Therapeutics, a clinical-stage biotechnology company. It functions as an autophagy modulator and is being developed for the treatment of neurodegenerative diseases. The development of TRE-T20 is expected to accelerate following the acquisition of Cyclo Therapeutics by Rafael Holdings.

Targets

Neuraminidase

Beyond the preview

Go deeper on TRE-T20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRE-T20.

Explore the full profile